Antibody selection wastes time and money

Researchers search the literature and vendor catalogs for antibodies

This can cost companies up to $3 million per year in wasted antibody spend

Infographic

They then validate 5-12 commercial antibodies or order custom antibodies

The process takes weeks to months, yet still can't prevent downstream risk

InfoMobile1
Search biomedical literature and vendor catalogs
InfoMobile2
Validate 5-12 antibodies and order custom antibodies
InfoMobile3
Spend up to $3 million per year on inappropriate antibodies
InfoMobile4
Create downstream risk from future antibody failure

Up to half of all commercially available antibodies are unreliable.

About 80% of life scientists use antibodies, spending $3 billion per year on more than 6 million products. But only half of commercially available antibodies are reliable1, and finding them is a challenge.

1. “Reproducibility Crisis: Blame It on the Antibodies.” Nature, 19 May 2015, www.nature.com/news/reproducibility-crisis-blame-it-on-the-antibodies-1.17586.

AI-Assisted Antibody Selection overcomes the challenge using machine learning

The technology collates relevant data, decodes it with AI, maps resulting knowledge with bioinformatic ontologies, and presents results in an intuitive interface.

How AI-Assisted Antibody Selection works

1
Collates the world’s antibody data from publications, vendors, and independent validations
Artificial Intelligence
2
Applies advanced AI to decode text and figures and understand use in experiments
Interface
3
Presents findings in novel interface to assist scientists in selecting antibodies for specific experiments
Antibody Data
1
Collates the world’s antibody data from publications, vendors and independent validations
2
Applies advanced AI to decode text and figures and understand use in experiments
3
Presents findings in novel UI to assist scientists in selecting antibodies for specific experiments

BenchSci is the world leader in AI-Assisted Antibody Selection

Backed by Google’s AI fund, Gradient Ventures, and trusted by more than 31,000 scientists worldwide, BenchSci is the industry standard for antibody selection

Request a Demo
Sign Up

Over 80% of scientists say BenchSci accelerates their work

Of scientists at 15 of the top 20 pharmaceutical companies that use BenchSci for AI-Assisted Antibody Selection2:

83

Report that BenchSci accelerates their work

76

Report purchasing fewer antibodies thanks to better antibody selection

75

Consider BenchSci an integral part of their workflow

2. On average, from surveys conducted on hundreds of industry scientists across various therapeutic areas and geographies.

In partnership with the world's leading scientific publishers

spring nature
wiley
wolters
pnas
faseb
jama
karger
aspet
asbmb

Learn More

See what customers, partners, and media say about BenchSci's impact

Tom, Chief Science Officer of BenchSci
Globe and Mail
Alphabet's AI Venture Capital Firm Makes First Investment in Canada with BenchSci
Read Article
https://www.theglobeandmail.com/business/article-alphabets-ai-venture-capital-firm-makes-first-investment-in-canada/
Picture of tissue on slides
BenchSci Case Studies
Dr. David Rimm on Antibodies, Reproducibility, and BenchSci
Read Case Study
https://blog.benchsci.com/dr.-david-rimm-on-antibodies-reproducibility-and-his-experience-with-benchsci

See how BenchSci can reduce consumable costs and accelerate projects in your organization

Request a Demo
Sign Up